Utah Admin. Code 156-17b-627

Current through Bulletin 2024-12, June 15, 2024
Section R156-17b-627 - Operating Standards - Prescription of Drugs or Devices by a Pharmacist
(1) Under Subsection 58-17b-601(1) and Section 58-17b-627, a pharmacist from a Class A or Class B pharmacy may prescribe a prescription drug or device as follows:
(a) Before prescribing, the pharmacist shall conduct a patient assessment that includes:
(i) current health status;
(ii) past medical history;
(iii) allergies;
(iv) medication sensitivities;
(v) rationale for care;
(vi) current medication; and
(vii) if the pharmacist should refer the patient to an appropriate health care provider or otherwise encourage the patient to seek further medical care.
(b) The pharmacist shall follow the guidelines for prescribing health care providers established by:
(i) the Centers for Disease Control and Prevention;
(ii) nationally accepted guidelines; and
(iii) the Department of Health and Human Services and the Division in collaboration with the Board, in the guidance documents incorporated by reference in Subsection (2)(a).
(c) The pharmacist shall comply with the requirements of Sections 58-17b-602 and 58-17b-609.
(d) The pharmacist shall develop and implement an appropriate follow-up care plan with the patient that includes:
(i) monitoring parameters for efficacy and safety;
(ii) adverse reactions; and
(iii) further medical care.
(e)
(i)
(A) The pharmacist shall notify the patient's primary care or other health care provider about the prescription within five business days of the prescribing.
(B) The prescription notification may be conveyed in writing, by electronic transmission, or by telephone.
(C) If the patient does not have a primary care or other health care provider, the pharmacist shall provide the prescription notification to the patient.
(D) The pharmacy shall maintain the prescription notification in the patient record for at least five years from the date of notification, in an immediately retrievable written or electronic format.
(ii) Each prescription notification shall include the following:
(A) prescribing pharmacist;
(B) pharmacy name;
(C) pharmacy phone number;
(D) patient;
(E) patient date of birth;
(F) drug or device;
(G) if dispensed, dispensed quantity;
(H) directions for use;
(I) refill; and
(J) identity of the patient's primary care or other health care provider, if any.
(2)
(a) A pharmacist may prescribe drugs or devices under Subsection 58-17b-627(3)(a) as established in the following guidance documents posted on the Division's website at dopl.utah.gov/pharm:
(i) Utah Guidance for Pre-Exposure and Post-Exposure Prophylaxis of HIV, adopted September 28, 2021;
(ii) Utah Guidance for Self-Administered Hormonal Contraceptives, adopted September 28, 2021;
(iii) Utah Guidance for Tobacco Cessation Products, adopted September 28, 2021; and
(iv) Utah Guidance for Naloxone, adopted September 28, 2021.
(b) The Division incorporates by reference the guidance documents in Subsection (2)(a).
(3)
(a) The Department of Health and Human Services may submit to the Division a written proposal that includes:
(i) under Subsection 58-17b-627(3)(a), designated public health concerns that the Department of Health and Human Services has determined can be addressed through pharmacist prescribing of drugs or devices; and
(ii) recommendations for updates to the guidance documents in Subsection (2); and
(b) after receipt of the designation, the Division:
(i) shall contact the Department of Health and Human Services to review its proposal; and
(ii) may review the rules made by the Division, including the guidance documents in Subsection (2), in accordance with Subsections 58-17b-627(3) and (4).
(4) The Division shall review the guidance documents in Subsection (2) biennially, in collaboration with:
(a) the Board;
(b) the individuals identified in Subsection 58-17b-627(4); and
(c) other persons as determined by the Division.

Utah Admin. Code R156-17b-627

Adopted by Utah State Bulletin Number 2022-03, effective 1/27/2022
Amended by Utah State Bulletin Number 2023-02, effective 1/5/2023